 Non-communicable diseases are the biggest killer of people in the world. These disproportionately affect the poor, and particularly in lower and middle-income countries. So a place like Senegal, about 30% of people who need access to diabetes medicines don't have any access. A WHO says we should get to at least 80% of people have access, if not more. And so you can see that the gap we have to go for is huge. We need to make sure that we have affordable medicines and supplies to go with NCD treatment. We need to work on data and data analysis and understand what's happening and get smarter. We need to work a lot on supply chain because this is a complex supply chain problem globally. We need to be more thoughtful about full-on end-to-end development. So what does that end-user need? What's the system they're working in? What are the tools they want to use? What's affordable? What's accessible? So we need to sort of plug it in into the actual continuum of care. We did this project around no-empty shelves, it was called, with Novodortis, focused on a number of urban communities or low-resource urban wards or slums, and looked at what the access to so diabetes medicines were. And we saw that three or four things. It was there were these separate places people went to get these rather than thinking about them in the context of their normal health care. There was never enough on the shelf. There might be enough insulin, but there wasn't a syringe or the testing strips or all these very expensive pieces. And so without it being looked at holistically, we are not seeing people being able to actually get to where they need to be. And that's true whether you're talking about a low-resource slum, a rural village, or even in a humanitarian crisis where we have people that not only are suffering from diabetes and hypertension, but actually are more likely to because of the conditions those situations create. We are pleased to have recently launched a coalition. We're bringing together people not only from different types of the private sector, but also different social sector players, academia, NGOs, multilaterals, foundations, and as well a number of governments at different levels. We know we have to keep working on prevention, but there are many people that have these diseases and are not getting treated today. And so how do we work on technical assistance? So what is the sort of needs we can identify? How do we improve the supplies? How do we improve the tools? What do we need to do on advocacy? How do we make sure that people see this issue and understand it and we can break down it into its parts? And then of course there's always resource mobilization, which is how do we ensure that we are raising the funding and thinking about innovative ways to support this effort globally. And so we're one of many partners that are really trying to get the world to see how kind of outrageous it is that kids and young people and young adults are dying of things that we all get treated for without thinking about.